Read the two statements on gene therapy for adenosine deaminase (ADA) deficiency.
Statement I: The first clinical gene therapy was given in 1990 to a fourteen-year-old girl with ADA deficiency. Her lymphocytes were grown in culture, given a functional ADA cDNA through a retroviral vector and returned to her.
Statement II: The engineered lymphocytes must be infused periodically because they are not immortal, so a permanent cure would need the ADA gene introduced into cells at an early embryonic stage.
Choose the correct option.